Ubs Group Ag Lyell Immunopharma, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 108,713 shares of LYEL stock, worth $65,227. This represents 0.0% of its overall portfolio holdings.

Number of Shares

108,713

Previous 84,813 28.18%

Holding current value

$65,227

Previous $122,000 22.95%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.13 - $1.88 $27,006 - $44,932	23,900 Added 28.18%	108,713 $150,000
Q2 2024 Aug 13, 2024	SELL	$1.3 - $3.01 $148,674 - $344,238	-114,365 Reduced 57.42%	84,813 $122,000
Q1 2024 May 13, 2024	SELL	$1.71 - $3.07 $33,622 - $60,362	-19,662 Reduced 8.98%	199,178 $444,000
Q4 2023 Feb 09, 2024	BUY	$1.39 - $2.35 $33,031 - $55,845	23,764 Added 12.18%	218,840 $424,000
Q3 2023 Nov 09, 2023	BUY	$1.45 - $3.35 $60,752 - $140,358	41,898 Added 27.35%	195,076 $286,000
Q2 2023 Aug 11, 2023	SELL	$1.89 - $3.86 $128,718 - $262,885	-68,105 Reduced 30.78%	153,178 $487,000
Q1 2023 May 12, 2023	SELL	$1.97 - $3.58 $373,793 - $679,279	-189,743 Reduced 46.16%	221,283 $522,000
Q4 2022 Feb 08, 2023	BUY	$2.78 - $8.09 $1.09 Million - $3.16 Million	390,708 Added 1922.96%	411,026 $1.43 Million
Q3 2022 Nov 10, 2022	BUY	$5.54 - $8.27 $83,654 - $124,877	15,100 Added 289.38%	20,318 $149,000
Q2 2022 Aug 10, 2022	BUY	$3.68 - $6.8 $802 - $1,482	218 Added 4.36%	5,218 $34,000
Q1 2022 May 16, 2022	SELL	$5.05 - $7.7 $47,510 - $72,441	-9,408 Reduced 65.3%	5,000 $25,000
Q4 2021 Feb 14, 2022	BUY	$7.13 - $15.19 $100,818 - $214,786	14,140 Added 5276.12%	14,408 $112,000
Q3 2021 Nov 15, 2021	BUY	$11.0 - $17.95 $2,948 - $4,810	268 New	268 $4,000

Others Institutions Holding LYEL

# of Institutions

120

Shares Held

142M

Call Options Held

18.1K

Put Options Held

200

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $149M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account